--- title: "Arcellx Acquired in Cash-and-CVR Deal, Going Private" type: "News" locale: "en" url: "https://longbridge.com/en/news/284448659.md" description: "Arcellx Inc. has been acquired in a cash-and-contingent value right (CVR) deal, going private after a tender offer of $115 per share plus a CVR worth up to $5, contingent on sales of its anito-cel product. The merger, completed on April 28, 2026, resulted in Arcellx becoming a wholly owned subsidiary, with significant changes in corporate governance. The company will delist from Nasdaq and terminate SEC reporting obligations. Analysts rate ACLX stock as a Hold with a price target of $115, reflecting a balanced view on its fundamentals and market support." datetime: "2026-04-28T20:55:40.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/284448659.md) - [en](https://longbridge.com/en/news/284448659.md) - [zh-HK](https://longbridge.com/zh-HK/news/284448659.md) --- # Arcellx Acquired in Cash-and-CVR Deal, Going Private ### Claim 55% Off TipRanks - Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions - Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks The latest update is out from Arcellx Inc ( (ACLX) ). On March 6, 2026, a purchaser launched a tender offer to acquire all outstanding shares of Arcellx Inc. common stock at $115 in cash plus a contingent value right (CVR) worth up to $5 per share, tied to cumulative worldwide sales of the company’s anito-cel product exceeding $6 billion by December 31, 2029. The offer expired on April 27, 2026, with about 77.2% of shares tendered, satisfying all conditions, and on April 28, 2026, the purchaser completed a merger under Delaware law, making Arcellx a wholly owned subsidiary and paying an aggregate of approximately $7.1 billion, including consideration for options and restricted stock units. Following the merger’s effective time on April 28, 2026, all remaining eligible shares were converted into the same cash-and-CVR merger consideration, employee equity awards were cashed out or canceled as specified, and Arcellx moved to delist its shares from Nasdaq and terminate its SEC registration and reporting obligations. The transaction also triggered a full overhaul of corporate governance: all pre-merger directors and officers resigned, the acquirer’s leadership team assumed control, and the company’s certificate of incorporation and bylaws were amended and restated, underscoring Arcellx’s transition from a public to a privately held, parent-controlled entity. The most recent analyst rating on (ACLX) stock is a Hold with a $115.00 price target. To see the full list of analyst forecasts on Arcellx Inc stock, see the ACLX Stock Forecast page. **Spark’s Take on ACLX Stock** According to Spark, TipRanks’ AI Analyst, ACLX is a Neutral. Score is balanced between weak fundamentals (no 2025 revenue, widening losses, and worsening cash burn) and strong external/market support from the announced takeout plus very strong price momentum. Negative earnings (negative P/E) remains a valuation headwind, but the corporate event materially offsets financial risk in the near term. To see Spark’s full report on ACLX stock, click here. **More about Arcellx Inc** Arcellx Inc. operates in the biopharmaceutical sector, focusing on the development and commercialization of innovative cell therapies. Its pipeline includes anitocabtagene autoleucel (anito-cel), a key product whose future worldwide sales are central to the contingent value rights structure in the company’s recent acquisition. **Average Trading Volume:** 2,428,752 **Technical Sentiment Signal:** Buy **Current Market Cap:** $6.73B Learn more about ACLX stock on TipRanks’ Stock Analysis page. ### Related Stocks - [ACLX.US](https://longbridge.com/en/quote/ACLX.US.md) ## Related News & Research - [Arcellx's (ACLX) "Neutral" Rating Reiterated at Cantor Fitzgerald](https://longbridge.com/en/news/284606217.md) - [Federated Hermes Inc. Cuts Position in Arcellx, Inc. $ACLX](https://longbridge.com/en/news/275580392.md) - [Arcellx CFO Michelle Gilson Sells Shares](https://longbridge.com/en/news/276392787.md) - [Arcellx CFO Michelle Gilson Sells Shares](https://longbridge.com/en/news/276280461.md) - [Assessing Arcellx (ACLX) Valuation After New Preclinical Data On BCMA CAR T Therapy Anito Cel](https://longbridge.com/en/news/276053786.md)